Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SciClone's Quarter Sales Growth Marred By FCPA Investigation Of China Operations

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - U.S. regulatory authorities have launched an investigation into the China operations of Hong Kong-based and Nasdaq-listed SciClone Pharmaceuticals, a specialty pharmaceutical company

You may also be interested in...



Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?

HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm

Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?

HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm

A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress

SINGAPORE - Major Chinese pharma companies are eyeing acquisitions of companies in lucrative Western markets to establish a global foothold, according to industry observers

Related Content

UsernamePublicRestriction

Register

SC075593

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel